RECARBRIO DIN 02565323
Health Canada record
| Active ingredient(s) | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG; RELEBACTAM 250 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01DH56 IMIPENEM, CILASTATIN AND RELEBACTAM |
| Original market date | 07-May-2026 |
| Current status date | 07-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IMIPENEM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02358344 | IMIPENEM AND CILASTATIN FOR INJECTION USP | SANDOZ CANADA INCORPORATED | Powder For Solution | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG | Marketed |
| 02351706 | TARO-IMIPENEM-CILASTATIN | SUN PHARMA CANADA INC | Powder For Solution | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG | Marketed |
| 02357437 | IMIPENEM AND CILASTATIN FOR INJECTION | PFIZER CANADA ULC | Powder For Solution | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG | Cancelled Post Market |
| 02357429 | IMIPENEM AND CILASTATIN FOR INJECTION | PFIZER CANADA ULC | Powder For Solution | IMIPENEM 250 MG; CILASTATIN (CILASTATIN SODIUM) 250 MG | Cancelled Pre Market |
| 02358336 | IMIPENEM AND CILASTATIN FOR INJECTION USP | SANDOZ CANADA INCORPORATED | Powder For Solution | IMIPENEM 250 MG; CILASTATIN (CILASTATIN SODIUM) 250 MG | Cancelled Post Market |
| 02439859 | IMIPENEM AND CILASTATIN FOR INJECTION, USP | METHAPHARM INC | Powder For Solution | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG | Cancelled Pre Market |
| 02439840 | IMIPENEM AND CILASTATIN FOR INJECTION, USP | METHAPHARM INC | Powder For Solution | IMIPENEM 250 MG; CILASTATIN (CILASTATIN SODIUM) 250 MG | Cancelled Pre Market |
| 00717274 | PRIMAXIN 250 | MERCK CANADA INC | Powder For Solution | IMIPENEM 250 MG; CILASTATIN (CILASTATIN SODIUM) 250 MG | Cancelled Post Market |
| 00717282 | PRIMAXIN 500 | MERCK CANADA INC | Powder For Solution | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG | Cancelled Post Market |
| 01911430 | PRIMAXIN IV 250/250 ADD-VANTAGE VIAL | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Powder For Solution | IMIPENEM 250 MG; CILASTATIN (CILASTATIN SODIUM) 250 MG | Cancelled Post Market |
| 01911449 | PRIMAXIN IV 500 | MERCK CANADA INC | Powder For Solution | IMIPENEM 500 MG; CILASTATIN (CILASTATIN SODIUM) 500 MG | Cancelled Post Market |
| 02351692 | TARO-IMIPENEM-CILASTATIN | SUN PHARMA CANADA INC | Powder For Solution | IMIPENEM 250 MG; CILASTATIN (CILASTATIN SODIUM) 250 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36807 | 2026-01-30 | New Drug Submission (NDS) |
International API supply for IMIPENEM
11 active FDA Drug Master Files.
Request a quote for RECARBRIO